Cargando…
Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis
INTRODUCTION: Type 2 diabetes mellitus (T2D) confers high atherosclerotic cardiovascular disease (ASCVD) risk. The metabolite trimethylamine N-oxide (TMAO) derived via gut flora has been linked to excess ASCVD. RESEARCH DESIGN AND METHODS: We analyzed data, biospecimens, and major adverse cardiovasc...
Autores principales: | Cardona, Andrea, O'Brien, Aaron, Bernier, Matthew C, Somogyi, Arpad, Wysocki, Vicki H, Smart, Suzanne, He, Xin, Ambrosio, Giuseppe, Hsueh, Willa Ann, Raman, Subha V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861061/ https://www.ncbi.nlm.nih.gov/pubmed/31798892 http://dx.doi.org/10.1136/bmjdrc-2019-000718 |
Ejemplares similares
-
Associations between physical activity and trimethylamine N-oxide in those at risk of type 2 diabetes
por: Argyridou, Stavroula, et al.
Publicado: (2020) -
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021) -
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023) -
A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment
por: Mariam, Arshiya, et al.
Publicado: (2021) -
Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial
por: Margolis, Karen L., et al.
Publicado: (2014)